New and emerging HDAC inhibitors for cancer treatment.

Abstract

Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner proteins has driven the rapid development of small-molecule inhibitors that target the cancer epigenome. Herein, we discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis. We examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.

• Authors: Alison C West, Ricky W Johnstone
• Journal: The Journal of clinical investigation (J Clin Invest) Vol. 124 Issue 1 Pg. 30-9 (Jan 2014) ISSN: 1558-8238 [Electronic] United States
• PMID: 24382387 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Histone Deacetylase Inhibitors
• Histone Deacetylases

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Histone Deacetylase Inhibitors (pharmacology, therapeutic use)
• Histone Deacetylases (metabolism)
• Humans
• Molecular Targeted Therapy
• Neoplasms (drug therapy, enzymology)